Mostrando 6 resultados de: 6
Filtros aplicados
Subtipo de publicación
Article(6)
Publisher
Canadian Journal of Cardiology(1)
Diabetes, Obesity and Metabolism(1)
International Journal of Stroke(1)
Journal of the American College of Cardiology(1)
New England Journal of Medicine(1)
Área temáticas
Enfermedades(6)
Farmacología y terapéutica(4)
Medicina y salud(3)
Fisiología humana(2)
Cirugía y especialidades médicas afines(1)
Área de conocimiento
Medicina interna(3)
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
ArticleAbstract: The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucaPalabras claves:antidiabetic drug, Cardiovascular disease, Clinical trial, diabetes complications, GLP-1 receptor agonistAutores:Atisso C.M., Avezum A.J., Basile J.N., Cardona-Munoz E.G., Chung N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., DIaz R., Franek E., Gerstein H.C., Hâncu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lakshmanan M., Lanas F., Leiter L.A., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:scopusRationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
ArticleAbstract: Background Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alPalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Ha J.W., Hart R.G., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Lanius V., Leong D.P., Lewis B.S., Liang Y., Liu L., Lonn E.M., Maggioni A.P., Metsarinne K.P., Misselwitz F., Moayyedi P., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yuan F., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial
ArticleAbstract: Background: Covert vascular disease of the brain manifests as infarcts, white matter hyperintensitiePalabras claves:Anticoagulant, Clinical trial, COGNITION, magnetic resonance imaging, prevention, silent infarctAutores:Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Cook-Bruns N., Dagenais G.R., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Ha J.W., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Wong G., Yuan F., Yusuf S., Zhu J.Fuentes:googlescopusRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
ArticleAbstract: Background: Direct oral anticoagulants are administered in fixed doses irrespective of body weight,Palabras claves:Cardiovascular Risk, DOAC, prevention, rivaroxabanAutores:Berkowitz S.D., Bhatt D.L., Dyal L., Eikelboom J.W., Fox K.A.A., Guzik T.J., Muehlhofer E., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Ramasundarahettige C., Yusuf S.Fuentes:googlescopusRivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
ArticleAbstract: Background: Patients with peripheral artery disease have an increased risk of cardiovascular morbidiPalabras claves:Autores:Aboyans V., ABRANTES J.A., AHUAD GUERRERO R.A., ALBISU DI GENNERO J.P., Alings M., ALVAREZ M., Anand S.S., Avezum A.J., Bangdiwala S.I., Barbieri M., BARTOLACCI I.P., Bhatt D.L., BORDONAVA A.P., Bosch J.J., Branch K.R.H., CACCAVO A., CARDONA M., CARTASEGNA L.U.I.S., Chacón C., Chen E., Commerford P.J., Connolly S.J., COSTABEL J.P., CUADRADO J., Cuneo C.A., DEBONNAIRE P., DIaz R., DRAN R.D., DUJARDIN K.A.R.L., ECTOR B.A.V.O., Eikelboom J.W., ELEGEERT I.V.A.N., FERRE PACORA F.A., Fox K.A.A., GARCIA DURAN R.O., GARRIDO M., Gomez Vilamajo O., GONZALEZ COLASO P.D.C., GRINFELD D., GUZMAN L.U.I.S., Hart R.G., HASBANI E., HERNANDES M., HOFFER E., HOMINAL M.A., HRABAR A., IBANEZ SAGGIA L.M., INDIO DO BRASIL C., Ingaramo A., Kakkar A.K., Keltai K., Leong D.P., LEROY J.E.A.N., Lewis B.S., LITVAK BRUNO M.R., LUCIARDI H.L., LUQUEZ H.U.G.O., MACIN S.M., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Maia L.N., MAJUL C.R., MANENTI E., Misselwitz F., Montaña O., NANI S., Novaretto L., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, PELAGAGGE M.J., Pogosova N., Precoma D.B., Reis G., ROSSI DOS SANTOS F., ROSSI P., Rydén L.E., SALA J., SARAIVA J.O.S.E., SARJANOVICH R.J., SCHIAVI L.B., SCHROE H., SCHYGIEL P.O., Störk S., VAN DE BORNE P., VAN DEN HEUVEL P.A.U.L., Vanassche T., Varigos J.D., VENSENTINI N., Verhamme P.B., VICO M., Vinereanu D., VITA N.A., VOGEL D., VRANCKX P., Widimsky P., Yan Duarte, Yusuf S., ZAIDMAN C., Zhu J., ZIMMERMANN S.L.Fuentes:scopusRivaroxaban with or without aspirin in stable cardiovascular disease
ArticleAbstract: BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effePalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhagirath V., Bhatt D.L., Bogaty P.M., Bosch J.J., Botto F., Branch K.R.H., Bruns N.C., Cairns J., Carlos Ernesto Peñaherrera, Casanova A., Catanese L., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DeMets D., Deng E., DIaz R., Donato Magno J., Edgar B. Rodas, Eikelboom J.W., Ertl G., Fabbri G., Felix Camilo, Fox K.A.A., Gabizon I., Gosselin G., Goto S., Guzik T.J., Ha J., Halon D., Hart R.G., Heldmann M., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamelas P.M., Lamy A., Lanas F., Lauw M., Leong D.P., Leong Y., Lewis B.S., Liang D., Liang Y., Liu L., Lonn E.M., Lutay Y., Maggioni A.P., Maly M., María José Paucar, Metsarinne K.P., Mikulik R., Misselwitz F., Moayyedi P., Momomura S.I., Nayar S., Ng K., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Perera K., Piegas L.S., Pirvu O., Pogosova N., Prins M., Probstfield J.L., Ramsay T., Ronner E., Rouleau J.L., Rydén L.E., Sato S., Schumi J., Sharma M., Shestakovska O., Shirley Guamán, Silvia Cáceres, Sleight P., Smyth A., Sokolova E., Steg P.G., Stoerk S., Störk S., Thabane L., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Wiendl M., Winkelmann B., Yan Duarte, Yang X., Yufereva Y., Yusoff K., Yusuf S., Zhu J.Fuentes:scopus